The pathway to commercialization for nanomedicine
- PMID: 17292057
- DOI: 10.1016/j.nano.2004.11.010
The pathway to commercialization for nanomedicine
Abstract
Nanomedicine is a global opportunity that will change the face of medicine and drug delivery in the next 20 years. To date, US firms have focused primarily on the science and less on the commercial application of nanomedicine. As a result, there remain significant obstacles in bringing a nanomedicine product to market. Overcoming those obstacles will require a multidisciplinary approach to commercialization. This article will look at the emerging nanomedicine market, the current view from the investment community, and some of the obstacles facing the commercialization of nanomedicine science.
Similar articles
-
Will the nanomedicine "patent land grab" thwart commercialization?Nanomedicine. 2005 Dec;1(4):346-50. doi: 10.1016/j.nano.2005.10.009. Nanomedicine. 2005. PMID: 17292108 Review. No abstract available.
-
Bringing nanomedicines to market: regulatory challenges, opportunities, and uncertainties.Nanomedicine. 2006 Jun;2(2):127-36. doi: 10.1016/j.nano.2006.04.005. Nanomedicine. 2006. PMID: 17292125 Review.
-
Commercializing nanotechnology.Nat Biotechnol. 2003 Oct;21(10):1137-43. doi: 10.1038/nbt1003-1137. Nat Biotechnol. 2003. PMID: 14520392 No abstract available.
-
Nanomedicine: real commercial potential or just hype?Int J Nanomedicine. 2006;1(4):373-4. doi: 10.2147/nano.2006.1.4.373. Int J Nanomedicine. 2006. PMID: 17722271 Free PMC article. No abstract available.
-
A look behind the rapid growth in healthcare IS.Healthc Inform. 1997 Jun;14(6):SS29-30. Healthc Inform. 1997. PMID: 10168120 No abstract available.
Cited by
-
The Light at the End of the Tunnel-Second Generation HPMA Conjugates for Cancer Treatment.Curr Opin Colloid Interface Sci. 2017 Sep;31:30-42. doi: 10.1016/j.cocis.2017.07.003. Epub 2017 Jul 28. Curr Opin Colloid Interface Sci. 2017. PMID: 29276426 Free PMC article.
-
Engineered nanomaterial-induced lysosomal membrane permeabilization and anti-cathepsin agents.J Toxicol Environ Health B Crit Rev. 2017;20(4):230-248. doi: 10.1080/10937404.2017.1305924. J Toxicol Environ Health B Crit Rev. 2017. PMID: 28632040 Free PMC article. Review.
-
Nanotechnology: intelligent design to treat complex disease.Pharm Res. 2006 Jul;23(7):1417-50. doi: 10.1007/s11095-006-0284-8. Epub 2006 Jun 21. Pharm Res. 2006. PMID: 16779701 Review.
-
Unique diagnostic and therapeutic roles of porphyrins and phthalocyanines in photodynamic therapy, imaging and theranostics.Theranostics. 2012;2(9):916-66. doi: 10.7150/thno.4571. Epub 2012 Oct 4. Theranostics. 2012. PMID: 23082103 Free PMC article.
-
Nanotechnology in medicine: from inception to market domination.J Drug Deliv. 2012;2012:389485. doi: 10.1155/2012/389485. Epub 2012 Mar 7. J Drug Deliv. 2012. PMID: 22506121 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Research Materials